Lobular MBC is different from ductal MBC. Lobular MBC is harder to detect, often detected at a later stage, and spreads to different places in the body compared to ductal MBC. Most lobular breast cancers are hormone receptor positive (ER+ and/or PR+) and HER2 negative. The number of people being diagnosed with lobular breast cancer is increasing compared to other types of breast cancer.
Visit the links below to learn more about lobular MBC and the latest research on this type of MBC.
Introduction to Lobular MBC
- Lobular Breast Cancer Alliance: Learn about lobular breast cancer here
- American Cancer Society: An article published in October 2025 shows that lobular breast cancer diagnoses are increasing faster than other types of breast cancer
Research for Lobular MBC
- Lobular Breast Cancer Alliance: Clinical trials are needed to better understand the role of a whole-body MRI scan and other types of scans in monitoring and treating lobular MBC
- Lobular Breast Cancer Alliance: Gene mutations in lobular MBC may help doctors choose personalized treatment (scroll to “P5-10-14: Treatment Patterns, Genomic Characteristics…”)
- Invasive Lobular Symposium (videos): View research results presented at the Invasive Lobular Symposium here
- University of California, San Francisco: UCSF researchers presented the PLUMB study, which aims to find better ways to monitor lobular MBC and increase clinical trial enrollment
Clinical Trials for Metastatic Lobular Breast Cancer
- Metastatic Trial Search: Trials open to people with metastatic lobular breast cancer
- Metastatic Trial Search: Trials specific for metastatic lobular breast cancer
Last Modified on December 1, 2025